Vanguard Capital Management’s Bicara Therapeutics BCAX Stock Holding History
Bought
Maintained
Sold
Other funds holding BCAX
SL
Vanguard Capital Management's BCAX Position: Q3 2026 in Review
Vanguard Capital Management reduced its Bicara Therapeutics (BCAX) stake by 0.14% in Q3 2026, selling an estimated $78.9K and leaving 2,213,487 shares worth $41.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2007.
Vanguard Capital Management first reported a position in BCAX in Q1 2026 and has held it in 3 quarters since. The position peaked at $65.8M in Q2 2026. 169 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.
- Vanguard Capital Management held 2,213,487 shares of Bicara Therapeutics worth $41.2M as of Q3 2026.
- Vanguard Capital Management sold 3,152 Bicara Therapeutics shares in Q3 2026, an estimated $78.9K.
- Bicara Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2007 holding.
- Vanguard Capital Management first reported a position in Bicara Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Bicara Therapeutics position peaked at $65.8M in Q2 2026.
- 169 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.